ZA200607096B - Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease - Google Patents

Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease

Info

Publication number: ZA200607096B
Authority: ZA; South Africa
Prior art keywords: hepatitis; virus; inhibitors; serine protease; sulfur compounds
Prior art date: 2004-02-27

Application number

ZA200607096A

Other languages

English (en)

Inventor

Bennet Frank

Huang Yuhua

Anil K Saksena

Liu Yi-Tsung

Venkatraman Srikanth

Sannigrahi Mousumi

Viyyoor M Girijavallabhan

Nair Latha

Raymond G Lovey

Hendrata Siska

Stephane L Bogen

Njoroge F George

Kevin X Chen

Arasappan Ashok

Velazquez Francisco

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-27

Filing date

2006-08-24

Publication date

2008-09-25

2006-08-24 Application filed by Schering Corp filed Critical Schering Corp

2008-09-25 Publication of ZA200607096B publication Critical patent/ZA200607096B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Crystallography & Structural Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200607096A 2004-02-27 2006-08-24 Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease ZA200607096B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US54867004P	2004-02-27	2004-02-27

Publications (1)

Publication Number	Publication Date
ZA200607096B true ZA200607096B (en)	2008-09-25

Family

ID=34961556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200607096A ZA200607096B (en)	2004-02-27	2006-08-24	Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease

Country Status (31)

Country	Link
US (1)	US8067379B2 (zh)
EP (1)	EP1730110B9 (zh)
JP (1)	JP4714732B2 (zh)
KR (2)	KR101316137B1 (zh)
CN (2)	CN101076516A (zh)
AR (1)	AR048241A1 (zh)
AT (1)	ATE470660T1 (zh)
AU (1)	AU2005222060A1 (zh)
BR (1)	BRPI0508085A (zh)
CA (1)	CA2557495C (zh)
CY (1)	CY1111212T1 (zh)
DE (1)	DE602005021760D1 (zh)
DK (1)	DK1730110T3 (zh)
EC (1)	ECSP066791A (zh)
ES (1)	ES2346233T3 (zh)
HK (1)	HK1095819A1 (zh)
HR (1)	HRP20100416T1 (zh)
IL (1)	IL177544A (zh)
MY (1)	MY145081A (zh)
NO (1)	NO20064358L (zh)
NZ (1)	NZ549223A (zh)
PE (1)	PE20051150A1 (zh)
PL (1)	PL1730110T3 (zh)
PT (1)	PT1730110E (zh)
RS (1)	RS51394B (zh)
RU (1)	RU2428428C9 (zh)
SG (1)	SG186041A1 (zh)
SI (1)	SI1730110T1 (zh)
TW (2)	TWI314927B (zh)
WO (1)	WO2005087731A1 (zh)
ZA (1)	ZA200607096B (zh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EE04023B1 (et)	1996-10-18	2003-04-15	Vertex Pharmaceuticals Incorporated	Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
NZ549223A (en) *	2004-02-27	2010-10-29	Schering Corp	Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) *	2004-02-27	2010-10-19	Schering Corporation	Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0426661D0 (en) *	2004-12-06	2005-01-05	Isis Innovation	Pyrrolidine compounds
US20070021351A1 (en) *	2005-06-02	2007-01-25	Schering Corporation	Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
KR20080021634A (ko) *	2005-06-02	2008-03-07	쉐링 코포레이션	약제학적 조성물 및 이를 사용한 치료 방법
WO2006130607A2 (en) *	2005-06-02	2006-12-07	Schering Corporation	Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20060276406A1 (en) *	2005-06-02	2006-12-07	Schering Corporation	Methods of treating hepatitis C virus
WO2006130554A2 (en) *	2005-06-02	2006-12-07	Schering Corporation	Methods of treating hepatitis c virus
WO2006130626A2 (en) *	2005-06-02	2006-12-07	Schering Corporation	Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
US20060275366A1 (en) *	2005-06-02	2006-12-07	Schering Corporation	Controlled-release formulation
NZ563361A (en)	2005-06-02	2011-02-25	Schering Corp	HCV protease inhibitors in combination with food
US20060276404A1 (en) *	2005-06-02	2006-12-07	Anima Ghosal	Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20070237818A1 (en) *	2005-06-02	2007-10-11	Malcolm Bruce A	Controlled-release formulation of HCV protease inhibitor and methods using the same
AR055395A1 (es)	2005-08-26	2007-08-22	Vertex Pharma	Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en)	2006-02-03	2010-10-19	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US20090220457A1 (en) *	2006-03-03	2009-09-03	Lahser Frederick C	Combinations comprising hcv protease inhibitor(s) and hcv ires inhibitor(s), and methods of treatment related thereto
MX2008011869A (es)	2006-03-16	2008-12-03	Vertex Pharma	Procedimientos e intermediarios para preparar compuestos estericos.
US20070287664A1 (en) *	2006-03-23	2007-12-13	Schering Corporation	Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
EP2007789B1 (en)	2006-04-11	2015-05-20	Novartis AG	Spirocyclic HCV/HIV inhibitors and their uses
DE102006059317A1 (de)	2006-07-04	2008-01-10	Evonik Degussa Gmbh	Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
BRPI0716060A2 (pt)	2006-08-17	2013-09-17	Boehringer Ingelheim Int	inibidores de polimerase viral.
EP2099430A2 (en) *	2006-12-07	2009-09-16	Schering Corporation	Ph sensitive matrix formulation
WO2008078563A1 (ja) *	2006-12-22	2008-07-03	Sumitomo Seika Chemicals Co., Ltd.	３－ベンジルオキシベンゼンチオールの製造方法
EP2064180B1 (en)	2006-12-22	2016-07-13	Merck Sharp & Dohme Corp.	4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
EP2064181A1 (en)	2006-12-22	2009-06-03	Schering Corporation	4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
MX2009006877A (es)	2006-12-22	2009-09-28	Schering Corp	Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
CA2693997C (en)	2007-08-03	2013-01-15	Pierre L. Beaulieu	Viral polymerase inhibitors
EP2197842B1 (en)	2007-08-29	2012-05-23	Schering Corporation	2, 3-substituted indole derivatives for treating viral infections
AU2008295484B2 (en)	2007-08-29	2013-09-26	Merck Sharp & Dohme Llc	Substituted indole derivatives and methods of use thereof
CN101842374A (zh)	2007-08-29	2010-09-22	先灵公司	用于治疗病毒感染的2，3-取代的氮杂吲哚衍生物
CA2699280A1 (en)	2007-09-14	2009-03-26	Schering Corporation	Method of treating hepatitis c patients
KR101218882B1 (ko)	2007-10-10	2013-01-07	노파르티스 아게	스피로피롤리딘, 및 ｈｃｖ 및 ｈｉｖ 감염에 대한 그의 용도
US8765757B2 (en)	2007-11-16	2014-07-01	Merck Sharp & Dohme Corp.	3-heterocyclic substituted indole derivatives and methods of use thereof
CN102317285A (zh)	2007-11-16	2012-01-11	先灵公司	3-氨基磺酰基取代的吲哚衍生物及其使用方法
EP2234977A4 (en)	2007-12-19	2011-04-13	Boehringer Ingelheim Int	VIRAL POLYMERASE INHIBITORS
US7964560B2 (en) *	2008-05-29	2011-06-21	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
CA2727620A1 (en)	2008-06-13	2009-12-17	Schering Corporation	Tricyclic indole derivatives and methods of use thereof
US20110207660A1 (en) *	2008-08-07	2011-08-25	Schering Corporation	Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US8188137B2 (en)	2008-08-15	2012-05-29	Avila Therapeutics, Inc.	HCV protease inhibitors and uses thereof
US20110286969A1 (en)	2008-12-12	2011-11-24	Schering Corporation	Deuterated compounds as hepatitis c virus (hcv) inhibitors
MX2011007195A (es)	2009-01-07	2013-07-12	Scynexis Inc	Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
AU2010253791A1 (en)	2009-05-29	2011-11-24	Merck Sharp & Dohme Corp.	Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
US8680294B2 (en)	2009-07-29	2014-03-25	Merck Sharp & Dohme Corp.	Enantio- and stereo specific synthesis of β-amino-α-hydroxy amides
WO2011066241A1 (en)	2009-11-25	2011-06-03	Schering Corporation	Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en)	2009-12-22	2011-07-21	Schering Corporation	Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
JP2013522202A (ja)	2010-03-09	2013-06-13	メルク・シャープ・エンド・ドーム・コーポレイション	縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法
EP2598149A4 (en)	2010-07-26	2014-09-10	Merck Sharp & Dohme	SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
EP2621902B1 (en)	2010-09-28	2017-04-12	Panacea Biotec Ltd	3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders
WO2012050848A1 (en)	2010-09-29	2012-04-19	Schering Corporation	Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012073249A1 (en)	2010-12-01	2012-06-07	Arch Pharmalabs Limited	A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs.
BR112013026345A2 (pt)	2011-04-13	2019-04-24	Merck Sharp & Dohe Corp.	composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2012142075A1 (en)	2011-04-13	2012-10-18	Merck Sharp & Dohme Corp.	2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en)	2011-09-08	2013-03-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en)	2011-09-08	2013-03-14	Merck Sharp & Dohme Corp.	Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en)	2011-09-08	2013-03-14	Merck Sharp & Dohme Corp.	Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en)	2011-09-14	2013-03-21	Merck Sharp & Dohme Corp.	Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015065817A1 (en)	2013-10-30	2015-05-07	Merck Sharp & Dohme Corp.	Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2017059411A1 (en) *	2015-10-01	2017-04-06	Memorial Sloan-Kettering Cancer Center	Inhibitors of menaquinone biosynthesis
WO2017059446A1 (en) *	2015-10-01	2017-04-06	Memorial Sloan-Kettering Cancer Center	Anthranilyl-adenosinemonosulfamate analogs and uses thereof
JP7076438B2 (ja)	2016-06-21	2022-05-27	オリオン・オフサルモロジー・エルエルシー	脂肪族プロリンアミド誘導体
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11351149B2 (en)	2020-09-03	2022-06-07	Pfizer Inc.	Nitrile-containing antiviral compounds
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2024153137A1 (zh) *	2023-01-17	2024-07-25	西藏海思科制药有限公司	一种手性氨基醇医药中间体的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE270326T1 (de)	1990-04-04	2004-07-15	Chiron Corp	Protease von hepatitis-c-virus
US5922757A (en)	1996-09-30	1999-07-13	The Regents Of The University Of California	Treatment and prevention of hepatic disorders
EE04023B1 (et)	1996-10-18	2003-04-15	Vertex Pharmaceuticals Incorporated	Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid
GB9623908D0 (en)	1996-11-18	1997-01-08	Hoffmann La Roche	Amino acid derivatives
AU757072B2 (en)	1997-08-11	2003-01-30	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C inhibitor peptide analogues
US6323180B1 (en)	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
AR022061A1 (es)	1998-08-10	2002-09-04	Boehringer Ingelheim Ca Ltd	Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
PT1268519E (pt)	2000-04-03	2005-08-31	Vertex Pharma	Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
DE60137207D1 (de)	2000-04-05	2009-02-12	Schering Corp	Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
RU2002131163A (ru)	2000-04-19	2004-06-27	Шеринг Корпорейшн (US)	Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты
AR029851A1 (es)	2000-07-21	2003-07-16	Dendreon Corp	Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US20020068702A1 (en)	2000-07-21	2002-06-06	Marguerita Lim-Wilby	Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en)	2000-07-21	2007-07-17	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
ES2341534T3 (es) *	2000-07-21	2010-06-22	Schering Corporation	Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
EP1303487A4 (en)	2000-07-21	2005-11-23	Schering Corp	NOVEL PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS
SV2003000617A (es) *	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP4368581B2 (ja)	2000-12-12	2009-11-18	シェーリングコーポレイション	Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としてのジアリールペプチド
US7816326B2 (en)	2004-02-27	2010-10-19	Schering Corporation	Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
NZ549223A (en) *	2004-02-27	2010-10-29	Schering Corp	Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
KR20080021634A (ko)	2005-06-02	2008-03-07	쉐링 코포레이션	약제학적 조성물 및 이를 사용한 치료 방법

2005
- 2005-02-24 NZ NZ549223A patent/NZ549223A/en not_active IP Right Cessation
- 2005-02-24 US US11/064,673 patent/US8067379B2/en active Active
- 2005-02-24 PL PL05723607T patent/PL1730110T3/pl unknown
- 2005-02-24 CN CNA2005800128593A patent/CN101076516A/zh active Pending
- 2005-02-24 BR BRPI0508085-1A patent/BRPI0508085A/pt not_active IP Right Cessation
- 2005-02-24 DE DE602005021760T patent/DE602005021760D1/de not_active Expired - Lifetime
- 2005-02-24 JP JP2007500955A patent/JP4714732B2/ja not_active Expired - Fee Related
- 2005-02-24 TW TW094105518A patent/TWI314927B/zh not_active IP Right Cessation
- 2005-02-24 EP EP05723607A patent/EP1730110B9/en not_active Expired - Lifetime
- 2005-02-24 ES ES05723607T patent/ES2346233T3/es not_active Expired - Lifetime
- 2005-02-24 WO PCT/US2005/005795 patent/WO2005087731A1/en active Application Filing
- 2005-02-24 KR KR1020067017257A patent/KR101316137B1/ko not_active IP Right Cessation
- 2005-02-24 DK DK05723607.7T patent/DK1730110T3/da active
- 2005-02-24 PE PE2005000220A patent/PE20051150A1/es not_active Application Discontinuation
- 2005-02-24 TW TW098107879A patent/TWI393704B/zh not_active IP Right Cessation
- 2005-02-24 RU RU2006134003/04A patent/RU2428428C9/ru active
- 2005-02-24 SG SG2012087664A patent/SG186041A1/en unknown
- 2005-02-24 KR KR1020127034290A patent/KR20130018418A/ko not_active Application Discontinuation
- 2005-02-24 AR ARP050100679A patent/AR048241A1/es not_active Application Discontinuation
- 2005-02-24 CN CN2012103533032A patent/CN103102389A/zh active Pending
- 2005-02-24 CA CA2557495A patent/CA2557495C/en not_active Expired - Fee Related
- 2005-02-24 AU AU2005222060A patent/AU2005222060A1/en not_active Abandoned
- 2005-02-24 SI SI200531086T patent/SI1730110T1/sl unknown
- 2005-02-24 RS RSP-2010/0360A patent/RS51394B/en unknown
- 2005-02-24 AT AT05723607T patent/ATE470660T1/de active
- 2005-02-24 PT PT05723607T patent/PT1730110E/pt unknown
- 2005-02-24 MY MYPI20050737A patent/MY145081A/en unknown
2006
- 2006-08-17 IL IL177544A patent/IL177544A/en not_active IP Right Cessation
- 2006-08-24 ZA ZA200607096A patent/ZA200607096B/xx unknown
- 2006-08-25 EC EC2006006791A patent/ECSP066791A/es unknown
- 2006-09-26 NO NO20064358A patent/NO20064358L/no not_active Application Discontinuation
2007
- 2007-03-19 HK HK07102951.6A patent/HK1095819A1/xx not_active IP Right Cessation
2010
- 2010-07-27 HR HR20100416T patent/HRP20100416T1/hr unknown
- 2010-09-01 CY CY20101100796T patent/CY1111212T1/el unknown

Also Published As

Publication number	Publication date
RU2428428C2 (ru)	2011-09-10
ATE470660T1 (de)	2010-06-15
CY1111212T1 (el)	2015-06-11
IL177544A (en)	2015-02-26
TW200530183A (en)	2005-09-16
EP1730110B9 (en)	2011-11-02
KR20060134083A (ko)	2006-12-27
CA2557495A1 (en)	2005-09-22
PE20051150A1 (es)	2006-01-16
AR048241A1 (es)	2006-04-12
NZ549223A (en)	2010-10-29
HK1095819A1 (en)	2007-07-27
DE602005021760D1 (de)	2010-07-22
KR101316137B1 (ko)	2013-10-10
DK1730110T3 (da)	2010-09-27
BRPI0508085A (pt)	2007-07-17
RS51394B (en)	2011-02-28
EP1730110A1 (en)	2006-12-13
JP4714732B2 (ja)	2011-06-29
WO2005087731A1 (en)	2005-09-22
CA2557495C (en)	2014-04-15
US20070042968A1 (en)	2007-02-22
ECSP066791A (es)	2006-11-16
AU2009225346A1 (en)	2009-11-05
PT1730110E (pt)	2010-09-14
JP2007525514A (ja)	2007-09-06
NO20064358L (no)	2006-11-24
WO2005087731A8 (en)	2006-06-22
RU2006134003A (ru)	2008-04-10
PL1730110T3 (pl)	2010-11-30
KR20130018418A (ko)	2013-02-21
TWI393704B (zh)	2013-04-21
ES2346233T3 (es)	2010-10-13
CN101076516A (zh)	2007-11-21
TWI314927B (en)	2009-09-21
EP1730110B1 (en)	2010-06-09
AU2005222060A1 (en)	2005-09-22
SG186041A1 (en)	2012-12-28
IL177544A0 (en)	2006-12-10
HRP20100416T1 (hr)	2010-09-30
US8067379B2 (en)	2011-11-29
CN103102389A (zh)	2013-05-15
MY145081A (en)	2011-12-15
TW200938526A (en)	2009-09-16
SI1730110T1 (sl)	2010-10-29
RU2428428C9 (ru)	2012-03-10

Publication	Publication Date	Title
HK1095819A1 (en)	2007-07-27	Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
IL177545A0 (en)	2006-12-10	Compounds as inhibitors of hepatitis c virus ns3 serine protease
ZA200607053B (en)	2009-02-25	Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
HK1099028A1 (en)	2007-08-03	Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
IL201427A0 (en)	2010-05-31	Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
IL177503A0 (en)	2006-12-10	Inhibitors of hepatitis c virus ns3 protease
HK1095820A1 (en)	2007-05-18	3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
IL176237A0 (en)	2006-10-05	Inhibitors of hepatitis c virus ns3/ns4a serine protease
IL174459A0 (en)	2006-08-01	Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
IL177628A0 (en)	2006-12-31	Novel ketoamides with cyclic p4s as inhibitors of ns3 serine protease of hepatitis c virus
TWI367211B (en)	2012-07-01	Hcv ns-3 serine protease inhibitors
DE602006009280D1 (de)	2009-10-29	Inhibitoren der hcv-ns3-protease
IL195512A0 (en)	2009-09-01	Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
EP2125870A4 (en)	2011-04-06	INHIBITORS OF HEPATITIS C NS3 PROTEASE
AU2009225346B2 (en)	2012-11-22	Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease